Neoantigen-specific T cell receptor (NeoTCR) (NeoTCR)

Neoantigen-specific T cell receptors (NeoTCRs) are heterodimeric surface proteins that enable the immune system to recognize and destroy cancer cells by targeting unique, mutation-derived peptides. These neoantigens arise from somatic mutations within the tumor genome and are not expressed by healthy tissues, providing a high degree of tumor specificity (Nature Reviews Cancer, 2017). The NeoTCR recognizes these peptides only when they are presented by specific Major Histocompatibility Complex (MHC) molecules, a process known as MHC restriction. In therapeutic contexts, NeoTCRs are utilized in adoptive cell transfer (ACT), where a patient's T cells are genetically modified to express a TCR specific to their own tumor's neoantigens (Science, 2014). This personalized approach aims to overcome the limitations of traditional immunotherapies by focusing the immune response on targets that are less likely to induce off-target autoimmune reactions. However, the efficacy of NeoTCR-based therapies can be hindered by tumor heterogeneity, HLA downregulation, and the immunosuppressive tumor microenvironment (Frontiers in Immunology, 2021). Ongoing clinical research focuses on identifying the most immunogenic neoantigens and optimizing TCR affinity to improve patient outcomes in solid tumors (Journal of Clinical Investigation, 2019).

Other names

Neoantigen-reactive T cell receptorMutation-specific T cell receptorNeo-TCRTumor-specific T cell receptor

Neoantigen-specific T cell receptors (NeoTCRs) function by binding to specific mutated peptides (neoantigens) presented on the cell surface by Major Histocompatibility Complex (MHC) molecules. This binding event triggers intracellular signaling cascades through the CD3 complex, leading to T cell activation, proliferation, and the directed release of cytotoxic granules (perforin and granzymes) to induce apoptosis in the target tumor cell (Nature Reviews Cancer, 2017; Science, 2014).